The Accuracy of Diagnostic Tests for Lyme Disease in Humans, A Systematic Review and Meta-Analysis of North American Research

Waddell, Lisa; Greig, Judy; Mascarenhas, Mariola; Harding, Shannon; Lindsay, L. Robbin; Ogden, Nicholas H.

doi:10.1371/journal.pone.0168613

Cited by 123 publications

(142 citation statements)

References 83 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…Dos meta-análisis de estudios serológicos de enfermedad de Lyme entre 1995 y 2016 encontraron que la media de sensibilidad para todas las pruebas era de 59,5% (50) y de 57,6% (51) . El western-blot presentó mayor sensibilidad que el ELISA, cuya sensibilidad estuvo alrededor del 53 % (50) .…”

Section: Limitaciones De La Evaluación Serológicaunclassified

“…El western-blot presentó mayor sensibilidad que el ELISA, cuya sensibilidad estuvo alrededor del 53 % (50) . Ya que lo que se miden con estas pruebas es el nivel de anticuerpos del hospedero, no es sorpresa que la sensibilidad fuese muy baja en la enfermedad aguda, comparado con aquella en convalescencia (50) , donde puede llegar a ser mayor del 99% (51) . Muchos de los estudios serológicos en los casos reportados no dan detalles del tipo de prueba diagnóstica utilizada, o si lo hacen, no mencionan el nombre del kit de ELISA o Western-blot.…”

Section: Limitaciones De La Evaluación Serológicaunclassified

“…Muchos de los estudios serológicos en los casos reportados no dan detalles del tipo de prueba diagnóstica utilizada, o si lo hacen, no mencionan el nombre del kit de ELISA o Western-blot. Esto es importante, ya que existe una gran variedad en la sensibilidad y especificidad de los diferentes kits comerciales de ELISA y de Westernblot (51) . Estos valores suelen mejorar si se realiza la serología combinando un ELISA con una prueba de Western-blot; sin embargo, esto también está sujeto a la marca de kit utilizada (51) .…”

Section: Limitaciones De La Evaluación Serológicaunclassified

“…Esto es importante, ya que existe una gran variedad en la sensibilidad y especificidad de los diferentes kits comerciales de ELISA y de Westernblot (51) . Estos valores suelen mejorar si se realiza la serología combinando un ELISA con una prueba de Western-blot; sin embargo, esto también está sujeto a la marca de kit utilizada (51) . La prueba serológica sólo puede ser útil dentro de un contexto clínico (52) , y su utilización en sujetos con síntomas subjetivos inespecíficos no es recomendable, ya que disminuye el valor predictivo positivo (53) .…”

Section: Limitaciones De La Evaluación Serológicaunclassified

See 3 more Smart Citations

Enfermedad de Lyme en el Perú. Una revisión clínica y epidemiológica

Cervantes

2018

Rev Peru Med Exp Salud Publica

View full text Add to dashboard Cite

This is a critical and organized review of all the available and updated information on Lyme disease and Borrelia infection in Peru. Several studies of positive serology to Borrelia burgdorferi and several cases of Lyme disease have been reported in Peru in the last two decades. New information suggests that new species of Borrelia burgdorferi sensu lato do exist in South America, and possibly in Peru. Future genetic and microbiology studies in this part of the continent, not only in cases with an indeterminate Western blot but in vectors and possible reservoirs as well, are necessary to measure the extent and clinical implications of these new Borrelia species.

show abstract

Section: Limitaciones De La Evaluación Serológicaunclassified

See 2 more Smart Citations

Enfermedad de Lyme en el Perú. Una revisión clínica y epidemiológica

Cervantes

2018

Rev Peru Med Exp Salud Publica

View full text Add to dashboard Cite

show abstract

“…It performs well in later-stage disseminated LD but is not a sensitive test for early, localized LD, since IgM antibodies usually take 2 to 3 weeks to develop to detectable levels 11,14 . In addition, prompt antibiotic treatment of some patients with EM may prevent the development of diagnostic levels of anti-B.…”

Section: Introductionmentioning

confidence: 99%

Measurement of organ-specific and acute-phase blood protein levels in early Lyme disease

Zhou

Qin

Sun

et al. 2019

Preprint

View full text Add to dashboard Cite

Lyme disease results from infection of humans with the spirochete Borrelia burgdorferi. The first and most common clinical manifestation is the circular, inflamed skin lesion referred to as erythema migrans; later manifestations result from infections of other body sites. Laboratory diagnosis of Lyme disease can be challenging in patients with erythema migrans because of the time delay in the development of specific diagnostic antibodies against Borrelia. Reliable blood biomarkers for the early diagnosis of Lyme disease in patients with erythema migrans are needed. Here, we performed selected reaction monitoring, a targeted mass spectrometry-based approach, to measure selected proteins that 1) are known to be predominantly expressed in one organ (i.e., organ-specific blood proteins) and whose blood concentrations may change as a result of Lyme disease, or 2) are involved in acute immune responses. In a longitudinal cohort of 40 Lyme disease patients and 20 healthy controls, we identified 10 proteins with significantly altered serum levels in patients at the time of diagnosis, and we also developed a 10-protein panel identified through multivariate analysis. In an independent cohort of patients with erythema migrans, six of these proteins, APOA4, C9, CRP, CST6, PGLYRP2 and S100A9, were confirmed to show significantly altered serum levels in patients at time of presentation.Nine of the 10 proteins from the multivariate panel were also verified in the second cohort. These proteins, primarily innate immune response proteins or proteins specific to liver, skin or white blood cells, may serve as candidate blood biomarkers requiring further validation to aid in the laboratory diagnosis of early Lyme disease.

show abstract

Exploring a possibility of using Raman spectroscopy for detection of Lyme disease

Farber

Morey

Krimmer

et al. 2021

Journal of Biophotonics

View full text Add to dashboard Cite

Lyme disease (LD), one of the most prevalent tick-borne diseases in the United States (US), is caused by Borreliella burgdorferi sensu stricto (Bb). To date, in the US, LD diagnostics is primarily based on validated two-tiered serological testing, which overall exhibits low sensitivity among other drawbacks. In the present study, a potential of Raman spectroscopy (RS) to detect Bb infection in mice has been explored. For that, C3H mice were infected with wild-type Bb strains, 297, B31, or B31-derived mutant, ΔvlsE. Blood samples taken prior to and post Bb infection were subjected to RS. The data demonstrated that RS did not directly detect Bb spirochetes in blood, but rather sensed biochemical changes associated with Bb infection. Despite Bb infection-associated blood changes detectable by RS were very limited, the partial least square discriminant analysis showed that the average true positive rates were 86% for 297 and 89% for B31 and ΔvlsE.

show abstract

The Accuracy of Diagnostic Tests for Lyme Disease in Humans, A Systematic Review and Meta-Analysis of North American Research

Cited by 123 publications

References 83 publications

Enfermedad de Lyme en el Perú. Una revisión clínica y epidemiológica

Enfermedad de Lyme en el Perú. Una revisión clínica y epidemiológica

Measurement of organ-specific and acute-phase blood protein levels in early Lyme disease

Exploring a possibility of using Raman spectroscopy for detection of Lyme disease

Contact Info

Product

Resources

About